DRR1 Gene Shows Promise as Potential Therapeutic Target for Lung Cancer

Researchers at Sichuan University in China have made a breakthrough in the fight against lung cancer by identifying a potential therapeutic target gene, DRR1. According to a study published in Oncology Reports, the DRR1 gene has been shown to have potent growth-suppressing properties in non-small cell lung cancer (NSCLC). The study, led by Q. Liu and colleagues, found that the gene acts through the apoptosis pathway in vivo, making it a promising candidate for treatment.

Key Takeaways:

• The DRR1 gene is a candidate tumor suppressor gene on human 3p21.1 that has been down-regulated in renal cell carcinoma.
• The gene was analyzed in 7 human lung cancer cell lines, with loss of DRR1 mRNA expression detected in 6 of the 7 lines.
• DRR1 protein expression was absent in 75% of human NSCLC specimens by immunostaining.
• Transfection of the DRR1 gene into DRR1-negative-expressing A549 cells resulted in significant cell growth suppression and apoptosis.
• The researchers concluded that DRR1 is a potent growth suppressor of NSCLC, acting through the apoptosis pathway in vivo.

Statistics:

• 6 out of 7 human lung cancer cell lines showed loss of DRR1 mRNA expression.
• 15 out of 20 (75%) human NSCLC specimens had absent DRR1 protein expression.
• Transfection of the DRR1 gene into A549 cells resulted in 50-60% cell growth suppression.
• Xenograft tumors in nude mice showed 20-30% tumor growth inhibition with DRR1 gene therapy.

Sources:

• Liu, Q., et al. (2009). Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1. Oncology Reports, 22(5), 1069-75.
• Xenografts.